Audentes' Gene Therapy Allows Ventilator Independence For Rare Disease
X-Linked Myotubular Myopathy Therapy Nears Market
Executive Summary
Audentes Therapeutics is aiming for regulatory submissions next year for its lead product, a skeletal muscle-targeted gene therapy, which continues to show promise in X-linked myotubular myopathy.